Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...

The recent update on the palazestrant + ribociclib combination in treating ER+/HER2- metastatic breast cancer shows encouraging results, with a high clinical benefit rate (CBR) across various patient ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...